CAPRELSA

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States

Active ingredients

The drug CAPRELSA contains one active pharmaceutical ingredient (API):

1 Vandetanib UNII YO460OQ37K - VANDETANIB

Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2 also known as kinase insert domain containing receptor [KDR]), epidermal growth factor receptor (EGFR) and RET tyrosine kinases. Vandetanib is also a sub-micromolar inhibitor of vascular endothelial receptor-3 tyrosine kinase. Read about Vandetanib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CAPRELSA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX04	Vandetanib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502313020022501, 502313020022601, 576720050064717, 576720050064817
Country: CA	Health Products and Food Branch	Identifier(s): 02378582, 02378590
Country: EE	Ravimiamet	Identifier(s): 1556759, 1556760
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 11749001, 11749002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 416002, 468773
Country: FR	Base de données publique des médicaments	Identifier(s): 65808531, 69269825
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 203587, 203590
Country: HK	Department of Health Drug Office	Identifier(s): 62086, 62087
Country: IE	Health Products Regulatory Authority	Identifier(s): 88786, 88787
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7139
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291041F1029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1065206, 1065207
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 101516, 101524
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100267875, 100267881
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W62995001, W62996001
Country: US	FDA, National Drug Code	Identifier(s): 58468-7820, 58468-7840